Tracking Real-Life results: can this breast cancer drug combo buy more time?
NCT ID NCT06148506
Summary
This study observes how well two different treatment approaches work for people with advanced HR+HER2- breast cancer in everyday Russian medical practice. It follows 376 patients who have already started treatment with either ribociclib plus hormone therapy or standard chemotherapy. Researchers will track how long patients stay on their treatment and measure quality of life, without changing anyone's care plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kaluga, Russia, 248007, Russia
-
Novartis Investigative Site
Barnaul, 656045, Russia
-
Novartis Investigative Site
Chelyabinsk, 454087, Russia
-
Novartis Investigative Site
Irkutsk, 664035, Russia
-
Novartis Investigative Site
Izhevsk, 426009, Russia
-
Novartis Investigative Site
Kemerovo, 650036, Russia
-
Novartis Investigative Site
Krasnodar, 350040, Russia
-
Novartis Investigative Site
Krasnoyarsk, 660022, Russia
-
Novartis Investigative Site
Moscow, 115304, Russia
-
Novartis Investigative Site
Moscow, 115522, Russia
-
Novartis Investigative Site
Moscow, 143423, Russia
-
Novartis Investigative Site
Nal'chik, 360051, Russia
-
Novartis Investigative Site
Podolsk, 142110, Russia
-
Novartis Investigative Site
Saransk, 430032, Russia
-
Novartis Investigative Site
Tambov, 392000, Russia
-
Novartis Investigative Site
Tver', 170008, Russia
-
Novartis Investigative Site
Ufa, 450054, Russia
-
Novartis Investigative Site
Vladikavkaz, 362002, Russia
-
Novartis Investigative Site
Yaroslavl, 150054, Russia
-
Novartis Investigative Site
Yekaterinburg, 620036, Russia
Conditions
Explore the condition pages connected to this study.